Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Research & Development (2017 - 2021)

Cogent Biosciences has reported Research & Development over the past 5 years, most recently at $20.5 million for Q4 2021.

  • Quarterly results put Research & Development at $20.5 million for Q4 2021, up 235.85% from a year ago — trailing twelve months through Dec 2021 was $55.9 million (up 117.24% YoY), and the annual figure for FY2025 was $269.8 million, up 15.96%.
  • Research & Development for Q4 2021 was $20.5 million at Cogent Biosciences, up from $14.8 million in the prior quarter.
  • Over the last five years, Research & Development for COGT hit a ceiling of $20.5 million in Q4 2021 and a floor of $5.0 million in Q3 2020.
  • Median Research & Development over the past 5 years was $9.3 million (2018), compared with a mean of $9.7 million.
  • Biggest five-year swings in Research & Development: tumbled 51.69% in 2020 and later skyrocketed 235.85% in 2021.
  • Cogent Biosciences' Research & Development stood at $7.6 million in 2017, then skyrocketed by 42.36% to $10.8 million in 2018, then fell by 3.82% to $10.4 million in 2019, then crashed by 41.01% to $6.1 million in 2020, then skyrocketed by 235.85% to $20.5 million in 2021.
  • The last three reported values for Research & Development were $20.5 million (Q4 2021), $14.8 million (Q3 2021), and $12.4 million (Q2 2021) per Business Quant data.